Selected article for: "oxygen saturation and present study"
Author: Samaee, Hamidreza; Mohsenzadegan, Monireh; Ala, Shahram; Sedigh Maroufi, Shahnam; Moradimajd, Parisa
Title: Tocilizumab for treatment patients with COVID-19: recommended medication for novel disease
  • Cord-id: xos48rkr
  • Document date: 2020_9_16
    • ID: xos48rkr
    Snippet: The coronavirus disease 2019 (COVID-19) virus has spread all over the world. Scientists are trying to discover drugs as effective treatment for patients with COVID-19. So far about 30 drugs have been introduced that one of them is Tocilizumab. Recently Tocilizumab has been introduced to treat patients with COVID-19 and researchers are investigating further the efficacy of this drug for different are patients. In Iran and China, some reports showed a positive effect of Tocilizumab on Saturation o
    Document: The coronavirus disease 2019 (COVID-19) virus has spread all over the world. Scientists are trying to discover drugs as effective treatment for patients with COVID-19. So far about 30 drugs have been introduced that one of them is Tocilizumab. Recently Tocilizumab has been introduced to treat patients with COVID-19 and researchers are investigating further the efficacy of this drug for different are patients. In Iran and China, some reports showed a positive effect of Tocilizumab on Saturation of Peripheral Oxygen (SPO2) but results of CT scan in patients in different. In some patients, CT scan showed reduced infiltration, however in other no change was observed. Unfortunately, until now there has been no definitive and effective treatment for patients with COVID-19. Although Tocilizumab has been accepted by China Health Commission to treat infected patients, its positive effects still cannot be predicted in all patients. Based on evidence of the Tocilizumab’s effect on the SARS COV 2, researchers hope this drug will make effective and promising treatment to improve lung tissue inflammation in patients with the fatal COVID-19 virus. The present study provides an overview of respiratory inflammation with COVID-19 and probable effect of Tocilizumab on SARS-COV 2.

    Search related documents:
    Co phrase search for related documents
    • accurate time and lung injury: 1
    • accurate time and lung tissue: 1, 2
    • active disease and adequate study: 1
    • active disease and liver test: 1
    • active disease and lopinavir ritonavir: 1, 2, 3, 4, 5, 6
    • active disease and lung inflammation: 1
    • active disease and lung injury: 1, 2, 3, 4
    • active disease and lung pathology: 1
    • active disease and lung tissue: 1, 2, 3, 4
    • active disease and macrophage neutrophil: 1
    • active infection and liver test: 1, 2
    • active infection and lopinavir ritonavir: 1, 2
    • active infection and lung inflammation: 1, 2, 3, 4, 5
    • active infection and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active infection and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active infection and lung tissue inflammation: 1, 2